Quarterly report pursuant to Section 13 or 15(d)

Strategic Alliances (Details)

v3.20.1
Strategic Alliances (Details) - USD ($)
1 Months Ended 3 Months Ended 30 Months Ended 63 Months Ended 94 Months Ended
May 05, 2020
Oct. 21, 2019
Oct. 12, 2017
Sep. 30, 2018
Jul. 31, 2018
May 31, 2016
Jan. 31, 2015
Dec. 31, 2010
Mar. 31, 2020
Mar. 31, 2019
Mar. 31, 2020
Mar. 31, 2020
Sep. 30, 2018
Dec. 31, 2019
Mar. 31, 2013
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Upfront payment from development and license agreement     $ 6,000,000                        
Milestone revenue recognized                     $ 0        
Contract liability                 $ 12,300,000   12,300,000 $ 12,300,000   $ 21,800,000  
VFMCRP | Development and License Agreement                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
License revenue, initial payment           $ 50,000,000                  
VFMCRP | Regulatory Milestones                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Additional milestone payment         $ 2,000,000.0                    
Additional milestone payment to be received           35,000,000                  
VFMCRP | Launch and Sales-based Milestones                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Additional milestone payment to be received           195,000,000                  
VFMCRP | Exclusive Option                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Additional milestone payment to be received           $ 555,000,000                  
Pfizer | Products                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Milestone revenue recognized                       0      
Additional milestone payment to be received             $ 275,000,000.0                
Annual height velocity at point in time   12 months                          
Non-refundable and non-creditable upfront payment             295,000,000.0                
Contract liability                 7,500,000   $ 7,500,000 $ 7,500,000      
Tesaro                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Milestone revenue recognized                 $ 0 $ 0          
Additional milestone payment               $ 85,000,000              
Upfront payment under license agreements               $ 6,000,000.0              
Milestone payment received                         $ 30,000,000    
Period from first commercial sale               12 years              
Written termination threshold               3 months              
Minimum | Pfizer | Products                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Each milestone payment             20,000,000.0                
Maximum | Pfizer | Products                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Each milestone payment             $ 90,000,000.0                
Pharmsynthez                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Ownership percentage, equity method                 9.00%   9.00% 9.00%      
Phio Pharmaceuticals                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Maximum milestone payments to be received                             $ 50,000,000.0
Phase Two Initiation                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Upfront payment from development and license agreement       $ 6,000,000                      
Regulatory and Development                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Milestone payment from development and license agreement     31,000,000                        
Sales Revenue                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Milestone payment from development and license agreement     $ 75,000,000                        
Subsequent Event | Sales Milestones | EirGen Pharma Limited                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Maximum milestone payments $ 210,000,000                            
Subsequent Event | Regulatory Milestones | EirGen Pharma Limited                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Maximum milestone payments $ 20,000,000